NIH Releases New Statement on Omicron Subvariants and Anti-SARS-CoV-2 Monoclonal Antibodies

October 19, 2022

The COVID-19 Treatment Guidelines Panel (the Panel) has issued a statement about the recent increase in certain SARS-CoV-2 Omicron subvariants circulating in the United States. These subvariants are likely to have reduced susceptibility to the anti-SARS-CoV-2 monoclonal antibodies bebtelovimab or tixagevimab plus cilgavimab (Evusheld).

At present, the prevalence of these subvariants is low to moderate and the Panel has not changed its recommendations. If the prevalence continues to increase, the Panel’s recommendations for bebtelovimab and for tixagevimab plus cilgavimab may be updated.

Please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website for more detailed information about these potentially resistant SARS-CoV-2 subvariants.